🧭 Timeline:
Dr. Richard M. Fleming and Nuclear Imaging

1968 to1970s — Foundational and Doctoral Physics and Nuclear Research

​

• Completes advanced doctoral physics training, including classified research involving positron–plasma annihilation (a conceptual precursor to PET physics).

• Establishes the physics and mathematical base that later informs his nuclear‑imaging methodologies.

​

1980s — Transition into Medicine and Cardiology

​

• Completes medical training and begins integrating nuclear physics with cardiovascular medicine.

• Early work focuses on regional blood‑flow measurement, a core principle of nuclear cardiology.

• Foundational work leading to the development of the InflammoThrombotic Immunologic Response (ITIR) Disease (ITIRD) Theory—originally The Fleming Unified Theory of Vascular Disease (FUTVD).

​

1990s — Nuclear Cardiology and Flow Quantification

​

• Develops the Quadratic Blood Flow Equation, a mathematical model for quantifying coronary blood‑flow reserve and early precursor of A.I.^2.

• Begins applying nuclear‑imaging principles to cardiology, particularly SPECT and early PET modalities.

• Establishes himself as a nuclear cardiologist, combining physics, imaging, and clinical cardiology.

• Begins combining ITIRD and early versions of FMTVDM to define heart disease and measure which treatments work and those that do not.

​

1990s to 2000s — SPECT and PET Imaging and Metabolic Measurement of ITIRD Using FMTVDM

​

• Earns special certifications in Positron Emission Tomography (PET).

• Expands research into metabolic imaging, focusing on inflammation, ischemia, thrombosis, immunologic function and perfusion (InflammoThrombotic Immunologic Response; ITIR) continuum.

• Continues to define what will become the FMTVDM calibrated—quantitative patented methodology.

​

2000s — Continued Development of FMTVDM Quantitative Nuclear Imaging

​

• Publishes work on quantitative nuclear imaging, arguing for measurement‑based imaging rather than qualitative or SUV interpretations.

• Continues refining isotope‑based measurement of blood flow and metabolic activity.

• Lays groundwork for a standardized, reproducible imaging method.

​

2010s — FMTVDM Patent and Imaging System

​

• Secures the patent for FMTVDM (Fleming Method for Tissue and Vascular Differentiation and Metabolism).

  • Patent covers methods and devices for measuring metabolic and regional blood‑flow differences using isotopes and imaging systems.

• Promotes the method as a calibrated, quantitative nuclear‑imaging standard.

• Continues to expand applications to cardiology, oncology, inflammatory and infectious diseases.

​

2020s — Continued Nuclear‑Imaging Advocacy

​

• Continues presentations at conferences on nuclear cardiology, nuclear medicine, and quantitative imaging.

• Emphasizes the shift from qualitative to quantitative nuclear imaging.

• Continues publishing and lecturing on ITIRD.

• Continues publishing and lecturing on PET, SPECT, and metabolic imaging.

​​

2026 — FMTVDM FRONTIER

​

• Launches FMTVDM Whole Body SPECT and PET.

• Initiates Select Nation Status (SNS) Country Initiative.

• Redefines Medical and Scientific Global Leadership.